Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: PFE US EQUITY

Pfizer Inc (New York: PFE, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website	www.pfizer.com
Number of Employees	88,000
Ticker:	PFE US

66 Hudson Blvd East New York, NY 10001 United States
Phone : 1-212-733-2323
Fax : 1-212-573-7851

28.58 -0.22 (-0.76%)

Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

-- -- -- - -- **FECHA:** **07/06/2024**

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	28.58	**Market Cap (MM)**	161,951.2
Open	28.75	**Shares Out. (MM)**	5,666.6
Previous Close	28.80	**Float %**	100.0%
Change	-0.75	**Shares sold short (MM)**	70,223,845.0
Change %	-2.54	**Dividend Yield %**	5.8
Day High/Day Low	29.1 / 28.6	**Diluted EPS Excl. XO**	
52 Wk High/52 Wk low	40.4 / 25.2	**P / Diluted EPS Before XO**	
Volume (MM)	26.45	**Beta**	0.70
Avg. Vol - 3 mo (MM)	40.65		



Financial Information (Currency: USD, in mm)			
Revenue - LTM	55,094.0	**Cash & ST Invst.**	12,690
EBIT - LTM	-2,018.0	**Total Assets**	226,501.0
EBITDA - LTM	4,521.0	**Total Debt**	75,041.0
Net Income - LTM	-309.0	**Total Liabilities**	137,213.0
Total Enterprise Value	219,838	**Total Equity**	89,288.0
TEV/ Total Revenue	3.9 x	**Cash from Operations - LTM**	8,578.0
TEV/ EBITDA	47.6 x	**Cash From Investing - LTM**	-33,861.0
		Cash from Financing -LTM	23,840.0

Company Notes

2015 Q3
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $470.000 from Asset Write Down
A loss of $529.000 from Restructuring
A loss of $163.000 from Impairment of Intangibles
A loss of $124.000 from Merger & Acquisition.
A gain of $35.000 from Disposal of assets.
A loss of 92.000 from various one time items.

2015 Q2
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $304.000 from Other One Time Items
A loss of $25.000 from Asset Write Down
A loss of $68.000 from Merger/Acquisition Expense
A gain of$ 5.000 from Investments, a gain from $ 15.000 from disposal of asset, A loss of $25.000 from impairment of asset
.

2015 Q1
GAAP Net Income includes, (in millions, after-tax):
a loss of $17.000 from Acquisition/Merger
a loss of $167.000 from Various One-Time Items
a gain of $5.000 from Discontinued Operations

2014 A1
GAAP Net Income includes, (in millions):
a pre-tax gain of $288.000 from Disposal of Assets
a pre-tax loss of $1,630.000 from Impairment/Legal
a pre-tax loss of $250.000 from Restructuring/Acquisition
an after-tax gain of $48.000 from Discontinued Operations

2014 Q1
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $140 from Restructuring
A loss of $694 from Legal Expense
A loss of $139 from Impairments and M & A Expense
A gain of $210 from Asset Disposal, Derivatives, and other

2013 A1
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $1431 from Restructuring, A gain of $1321 from Legal Expense, A loss of $144 from M & A Expense, A gain of $38 from Derivatives,A loss of $1224from Impairments,A gain of $125 from Asset Disposal, A gain of $195 from Sale of Investment
A gain of $10,623.000 from Discontinued Operations

2013 Q4
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $708 from Restructuring, A loss of $120 from Legal Expense, A loss of $34 from M & A Expense,A gain of $5 from Derivatives, A loss of $176 from Impairments,A gain of $125 from Assets Disposal,A gain of $95 from Sale of Investment
a loss of $58.000 from Discontinued Operations

2013 Q3
GAAP Net Income includes, (in millions, after-tax):
a loss of $54.000 from Acquisition/Merger
a loss of $1,223.000 from Various One-Time Items
a gain of $11.000 from Discontinued Operations

Key Board Members

	Name	Title	Organization
1	Ronald E Blaylock "Ron"	Founder	Blaylock & Partners Lp
2		Managing Partner/Co-Founder	Gennx360 Capital Partners
3		Board Member	Pfizer Inc
4		Board Member	Carmax Inc
5		Board Member	Wr Berkley Corp
6		Board Member	Mebane Charitable Foundation I
7	Susan Desmond-Hellmann "Sue"	Board Member	Openai
8		Board Member	Pfizer Inc
9		Board Member	National Resilience Inc
#		Board Member	Pfizer Venture Investments
#	Suzanne Nora Johnson	Co-Chairman	Brookings Institution/The
#		Chairman	Intuit Inc
#		Board Member	Pfizer Inc
#		Trustee	University Of Southern Califor
#		Chairman	John & Mary R Markle Foundatio
#		Trustee	Carnegie Institution Of Washin
#		Trustee	University Of Southern Califor
#		Board Member	Women'S World Banking Inc
#		Board Member	Technoserve Inc
#		Board Member	Council For Excellence In Govt
#		Board Member	Children Now Inc
#		Board Member	American Red Cross
#		Board Member	Visa Intl Inc
#	Shantanu Narayen	Co-Founder	Pictra Inc
#		Vice Chairman	Us-India Strategic Partnership
#		Chairman/President/Ceo	Adobe Ventures Lp
#		Chair/Ceo	Adobe Inc
#		Lead Director	Pfizer Inc
#		Chairman	Adobe Foundation

Bloomberg

Company In Depth Fundamentals - Key Stats

Ticker: PFE US EQUITY

Period Type Annuals

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Annuals

Key Financials

FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0fs	1FY	2FY	3FY
	Actuals							LTM	Estimates		
For the Fiscal Period Ending	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/03/2024	31/03/2024	31/12/2024	31/12/2025	31/12/2026
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Total Revenue	52,546.0	53,647.0	40,905.0	41,908.0	81,288.0	100,330.0	58,496.0	46,928.0	58,496.0	13,023.8	13,023.8
Growth Over Prior Year	*(0.5%)*	*2.1%*	*(23.8%)*	*2.5%*	*94.0%*	*23.4%*	*(41.7%)*	--	*2.3%*	*2.3%*	*2.3%*
Gross Profit	41,318.0	42,399.0	32,851.0	33,216.0	50,467.0	65,986.0	33,542.0	--	--	--	
Margin %	*78.6%*	*79.0%*	*80.3%*	*79.3%*	*62.1%*	*65.8%*	*57.3%*	--	--	--	--
EBITDA	19,991.0	20,385.0	20,948.0	13,336.0	25,131.0	40,690.0	7,351.0	--	5,785.0	5,785.0	5,785.0
Margin %	*38.0%*	*38.0%*	*51.2%*	*31.8%*	*30.9%*	*40.6%*	*12.6%*	--	*9.9%*	*44.4%*	*44.4%*
EBIT	13,722.0	14,001.0	14,817.0	8,166.0	19,433.0	34,944.0	222.0	--	3,600.7	3,600.7	3,600.7
Margin %	*26.1%*	*26.1%*	*36.2%*	*19.5%*	*23.9%*	*34.8%*	*0.4%*	--	*6.2%*	*27.6%*	*27.6%*
Earnings from Cont. Ops.	21,353.0	11,179.0	10,738.0	7,020.0	22,459.0	31,401.0	2,173.0	--	--	--	--
Margin %	*40.6%*	*20.8%*	*26.3%*	*16.8%*	*27.6%*	*31.3%*	*3.7%*	--	--	--	--
Net Income	21,308.0	11,153.0	16,026.0	9,616.0	21,979.0	31,372.0	2,119.0	--	2,559.7	2,559.7	2,559.7
Margin %	*40.6%*	*20.8%*	*39.2%*	*22.9%*	*27.0%*	*31.3%*	*3.6%*	--	*4.4%*	*19.7%*	*19.7%*
Diluted EPS Excl. Extra Items	3.5	1.9	1.9	1.2	3.9	5.5	0.4	--	0.5	0.5	0.5
Growth Over Prior Year	*200.9%*	*(47.2%)*	*1.6%*	*(34.4%)*	*216.9%*	*39.2%*	*(93.2%)*	--	*(32.5%)*	*(32.5%)*	*(32.5%)*

Current Capitalization (Millions)

Currency	USD
Share Price (USD)	28.58
Shares Out.	5,666.59
Market Capitalization (USD)	161,951.23
- Cash & Short Term Investments	0.00
+ Total Debt	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	219,838.23
Book Value of Common Equity	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	0.00
= Total Capital	0.00



PE Ratio

Valuation Multiples based on Current Capitalization

	Actual	LTM	Estimates		
For the Fiscal Period Ending	31/03/2024	31/03/2024	31/03/2024	31/03/2024	31/03/2024
TEV/Total Revenue	3.8x	--	9.4x	9.4x	9.4x
TEV/EBITDA	30.6x	--	--	--	--
TEV/EBIT	656.4x	--	--	--	--
P/Diluted EPS Before Extra	77.8x	--			
P/BV	1.8x	--	1.8x	1.8x	1.8x
Price/Tang BV	--	--			

Valuation Multiples for Chart

For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	35.4x	12.7x	12.7x	12.7x
TEV / EBITDA	47.6x	0.0x	0.0x	0.0x
Price / CF	18.8x	0.0x	0.0x	0.0x
Price / Book	1.8x	1.8x	1.8x	1.8x
Dividend Yield	5.8x	5.4x	5.4x	5.4x



Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud   Industry: Productos farmacéuticos   Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Currency	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*	*USD*
Revenue	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00	91,793.00	50,914.00
Other Revenue	-	-	-	-	-	-	-	-	-	8,537.00	7,582.00
Total Revenue	**51,584.00**	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,908.00**	**81,288.00**	**100,330.00**	**58,496.00**
Cost Of Goods Sold	9,586.00	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,692.00	30,821.00	34,344.00	24,954.00
Gross Profit	**41,998.00**	**40,028.00**	**39,203.00**	**40,495.00**	**41,318.00**	**42,399.00**	**32,851.00**	**33,216.00**	**50,467.00**	**65,986.00**	**33,542.00**
Selling General & Admin Exp.	15,537.00	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,209.00	16,974.00	16,005.00	17,908.00
R & D Exp.	6,678.00	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,405.00	10,360.00	11,428.00	10,679.00
Depreciation & Amort.	4,599.00	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,436.00	3,700.00	3,609.00	4,733.00
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	**26,814.00**	**26,779.00**	**27,379.00**	**28,489.00**	**27,596.00**	**28,398.00**	**18,034.00**	**25,050.00**	**31,034.00**	**31,042.00**	**33,320.00**
Operating Income	**15,184.00**	**13,249.00**	**11,824.00**	**12,006.00**	**13,722.00**	**14,001.00**	**14,817.00**	**8,166.00**	**19,433.00**	**34,944.00**	**222.00**
Interest Expense	1,414.00	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00	1,238.00	2,209.00
Interest Income	403.00	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00	251.00	1,624.00
Net Interest Exp.	**1,011.00**	**935.00**	**728.00**	**716.00**	**879.00**	**983.00**	**1,348.00**	**1,376.00**	**1,255.00**	**987.00**	**585.00**
Currency Exchange Gains (Loss)	-	-	806.00	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	(1,543.00)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(707.00)	(6,133.00)	(772.00)	(1,421.00)
EBT Excl. Unusual Items	**15,716.00**	**12,240.00**	**8,965.00**	**8,351.00**	**12,305.00**	**11,885.00**	**11,321.00**	**7,497.00**	**24,311.00**	**34,729.00**	**1,058.00**
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	**15,716.00**	**12,240.00**	**8,965.00**	**8,351.00**	**12,305.00**	**11,885.00**	**11,321.00**	**7,497.00**	**24,311.00**	**34,729.00**	**1,058.00**
Income Tax Expense	4,306.00	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	477.00	1,852.00	3,328.00	(1,115.00)
Earnings from Cont. Ops.	**11,410.00**	**9,120.00**	**6,975.00**	**7,228.00**	**21,353.00**	**11,179.00**	**10,738.00**	**7,020.00**	**22,459.00**	**31,401.00**	**2,173.00**
Extraord. Item & Account. Change	(10,662.00)	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,631.00)	434.00	(6.00)	15.00
Minority Int. in Earnings	69.00	33.00	26.00	31.00	47.00	36.00	30.00	35.00	46.00	35.00	39.00
Net Income	**22,003.00**	**9,135.00**	**6,960.00**	**7,215.00**	**21,308.00**	**11,153.00**	**16,026.00**	**9,616.00**	**21,979.00**	**31,372.00**	**2,119.00**
Pref. Dividends	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	**22,001.00**	**9,133.00**	**6,958.00**	**7,213.00**	**21,307.00**	**11,152.00**	**16,026.00**	**9,616.00**	**21,979.00**	**31,372.00**	**2,119.00**
Abnormal Losses (Gains)	1,106.00	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	3,849.00	1,267.00	5,299.00	6,135.00
Tax Effect on Abnormal Items	(344.00)	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(813.67)	(1,148.26)	(1,129.06)	(1,266.11)
NI to Common Excl. Extra Items	**22,763.00**	**11,484.70**	**10,447.85**	**12,925.85**	**12,464.46**	**13,531.33**	**12,421.11**	**12,651.33**	**22,097.74**	**35,541.94**	**6,987.89**
Per Share Items											
Basic EPS	3.23	1.44	1.13	1.18	3.57	1.90	2.88	1.73	3.92	5.59	0.38
Basic EPS Excl. Extra Items	1.67	1.43	1.13	1.18	3.57	1.90	1.92	1.26	4.00	5.59	0.38
Weighted Avg. Basic Shares Out.	6,813.00	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00	5,608.00	5,643.00
Diluted EPS	3.19	1.42	1.11	1.17	3.52	1.87	2.82	1.71	3.85	5.47	0.37
Diluted EPS Excl. Extra Items	1.65	1.41	1.11	1.17	3.52	1.86	1.89	1.24	3.93	5.47	0.37
Weighted Avg. Diluted Shares Out.	6,895.00	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00	5,733.00	5,709.00
Normalized Basic EPS	2.22	2.26	2.20	2.40	2.65	3.00	2.95	2.22	4.42	6.58	1.85
Normalized Diluted EPS	1.76	1.78	1.67	2.10	2.06	2.26	1.25	1.78	3.95	6.20	1.22
Dividends per Share											
Payout Ratio %	57.68	72.65	99.57	101.55	36.43	72.73	75.93	121.68	39.33	28.81	436.55
Supplemental Items											
EBITA	19,783.00	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,995.00	23,640.00	39,235.00	5,794.00
EBIT	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,166.00	19,433.00	34,944.00	222.00
As Reported Total Revenue*	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00	100,330.00	58,496.00
Effective Tax Rate %	27.40	25.49	22.20	13.45	-	5.94	5.15	6.36	7.62	9.58	-
Normalized Net Income	12,101.00	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,020.33	22,531.74	35,535.94	7,002.89
Interest Capitalized	32.00	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00	124.00	160.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	523.00	586.00	669.00	691.00	840.00	949.00	687.00	756.00	1,182.00	872.00	525.00
Stock-Based Comp., Total	**523.00**	**586.00**	**669.00**	**691.00**	**840.00**	**949.00**	**687.00**	**756.00**	**1,182.00**	**872.00**	**525.00**

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Currency	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**
ASSETS											
Cash And Equivalents	2,183.00	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,784.00	1,944.00	416.00	2,853.00
Short Term Investments	30,225.00	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00	22,316.00	9,837.00
Total Cash & ST Investments	**32,408.00**	**36,122.00**	**23,290.00**	**17,850.00**	**19,992.00**	**18,833.00**	**9,646.00**	**12,221.00**	**31,069.00**	**22,732.00**	**12,690.00**
Accounts & Notes Receivable	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00	11,479.00	10,952.00	11,177.00
Total Receivables	**9,357.00**	**8,401.00**	**8,176.00**	**8,225.00**	**8,221.00**	**8,025.00**	**6,772.00**	**7,930.00**	**11,479.00**	**10,952.00**	**11,177.00**
Inventories	6,166.00	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,046.00	9,059.00	8,981.00	10,190.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	8,313.00	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,870.00	8,086.00	8,594.00	9,276.00
Total Current Assets	**56,244.00**	**55,595.00**	**43,804.00**	**38,949.00**	**41,141.00**	**49,926.00**	**32,803.00**	**35,067.00**	**59,693.00**	**51,259.00**	**43,333.00**
Net Property, Plant & Equipment	**12,397.00**	**11,760.00**	**13,766.00**	**13,318.00**	**13,865.00**	**13,385.00**	**14,257.00**	**15,293.00**	**17,721.00**	**19,275.00**	**21,865.00**
Long-term Investments	16,406.00	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00	15,069.00	15,368.00
Deferred Charges, LT	1,554.00	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00	6,693.00	3,706.00
Other Long-Term Assets	85,500.00	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,224.00	79,195.00	104,909.00	142,229.00
Total Assets	**172,101.00**	**167,566.00**	**167,381.00**	**171,615.00**	**171,797.00**	**159,422.00**	**167,594.00**	**154,229.00**	**181,476.00**	**197,205.00**	**226,501.00**
LIABILITIES											
Accrued Exp.	1,792.00	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,058.00	3,332.00	3,407.00	2,776.00
Short-term Borrowings	6,027.00	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,024.00	2,690.00	3,565.00	10,877.00
Accounts Payable	3,234.00	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,309.00	5,578.00	6,809.00	6,710.00
Curr. Income Taxes Payable	678.00	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00	1,587.00	2,349.00
Other Current Liabilities	11,635.00	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,582.00	14,480.00	29,806.00	26,770.00	25,082.00
Total Current Liabilities	**23,366.00**	**21,587.00**	**29,398.00**	**31,115.00**	**30,427.00**	**31,858.00**	**37,303.00**	**25,920.00**	**42,672.00**	**42,138.00**	**47,794.00**
Long-Term Debt	30,462.00	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,247.00	38,705.00	35,481.00	64,164.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	41,653.00	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,589.00	22,637.00	23,669.00	25,255.00
Total Liabilities	**95,481.00**	**95,945.00**	**102,383.00**	**111,775.00**	**100,141.00**	**95,664.00**	**104,147.00**	**90,756.00**	**104,014.00**	**101,288.00**	**137,213.00**
Pref. Stock, Non-Redeem.	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-	-	-	-
Total Pref. Equity	**33.00**	**29.00**	**26.00**	**24.00**	**21.00**	**19.00**	**17.00**	**-**	**-**	**-**	**-**
Minority Interest	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00
Additional Paid In Capital	77,736.00	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00	92,278.00	93,109.00
Retained Earnings	69,732.00	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	96,770.00	103,394.00	125,656.00	118,353.00
Treasury Stock	(67,923.00)	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)	(113,969.00)	(114,487.00)
Comprehensive Inc. and Other	(3,271.00)	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,638.00)	(11,688.00)	(5,897.00)	(8,304.00)	(7,961.00)
Total Common Equity	**76,587.00**	**71,592.00**	**64,972.00**	**59,816.00**	**71,635.00**	**63,739.00**	**63,430.00**	**63,473.00**	**77,462.00**	**95,917.00**	**89,288.00**
Total Equity	**76,620.00**	**71,621.00**	**64,998.00**	**59,840.00**	**71,656.00**	**63,758.00**	**63,447.00**	**63,473.00**	**77,462.00**	**95,917.00**	**89,288.00**
Total Liabilities And Equity	**172,101.00**	**167,566.00**	**167,381.00**	**171,615.00**	**171,797.00**	**159,422.00**	**167,594.00**	**154,229.00**	**181,476.00**	**197,205.00**	**226,501.00**
Supplemental Items											
Total Shares Out. on Filing Date	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00
Total Shares Out. on Balance Sheet Date	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00
Book Value/Share	11.92	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74	17.03	15.77
Tangible Book Value	(5,630.00)	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,011.00)	(14,810.00)	2,846.00	915.00	(43,667.00)
Tangible Book Value/Share	(0.88)	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.66)	0.51	0.16	(7.73)
Total Debt	36,489.00	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,271.00	41,395.00	39,046.00	75,041.00
Net Debt	4,081.00	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,050.00	10,326.00	16,314.00	62,351.00
Total Minority Interest	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	505.00	510.00	867.00	793.00	788.00	546.00	672.00	738.00	994.00	859.00	1,007.00
Work in Progress Inventory	3,445.00	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,430.00	4,424.00	5,519.00	5,688.00
Finished Goods Inventory	2,216.00	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,878.00	3,641.00	2,603.00	3,495.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	478.00	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00	449.00	470.00
Full Time Employees	77,700.00	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00	83,000.00	88,000.00

Bloomberg

Company In Depth Fundamentals - Cash Flow Statement

Ticker:	PFE US EQUITY	Sort	Ascend	Currency Selection	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting Standard	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Cash Flow											
For the Fiscal Period Ending	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Currency	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***
Net Income	**22,003.00**	**9,135.00**	**6,960.00**	**7,215.00**	**21,308.00**	**11,153.00**	**16,026.00**	**9,616.00**	**21,979.00**	**31,372.00**	**2,119.00**
Depreciation & Amort., Total	**6,410.00**	**5,537.00**	**5,157.00**	**5,757.00**	**6,269.00**	**6,384.00**	**5,755.00**	**4,777.00**	**5,191.00**	**5,064.00**	**6,290.00**
Other Non-Cash Adj	(11,343.00)	1,300.00	2,730.00	2,561.00	(12,169.00)	(702.00)	(3,583.00)	2,880.00	10,270.00	(8,668.00)	(3,804.00)
Changes in Non-Cash Capital	614.00	1,112.00	(159.00)	368.00	1,394.00	(1,008.00)	(5,610.00)	(2,870.00)	(4,860.00)	1,499.00	4,095.00
Cash from Ops.	**17,684.00**	**17,084.00**	**14,688.00**	**15,901.00**	**16,802.00**	**15,827.00**	**12,588.00**	**14,403.00**	**32,580.00**	**29,267.00**	**8,700.00**
Capital Expenditure	(1,206.00)	(1,199.00)	(1,397.00)	(1,823.00)	(1,956.00)	(2,042.00)	(2,046.00)	(2,252.00)	(2,711.00)	(3,236.00)	(3,907.00)
Sale of Property, Plant, and Equipment	-	-	-	-	-	-	-	-	-	-	-
Cash Acquisitions	(11,020.00)	(10,718.00)	(9,542.00)	(8,011.00)	(3,537.00)	(1,797.00)	(201.00)	(597.00)	(1,068.00)	(1,913.00)	(204.00)
Proceeds from Investment	7,555.00	6,145.00	6,929.00	11,254.00	3,579.00	6,244.00	232.00	723.00	649.00	641.00	1,979.00
Divestitures	-	-	-	-	-	-	-	-	-	-	-
Invest. in Marketable & Equity Securt.	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	(5,873.00)	118.00	1,030.00	(9,231.00)	(2,826.00)	2,120.00	(1,930.00)	(2,145.00)	(19,416.00)	(11,275.00)	(30,146.00)
Cash from Investing	**(10,544.00)**	**(5,654.00)**	**(2,980.00)**	**(7,811.00)**	**(4,740.00)**	**4,525.00**	**(3,945.00)**	**(4,271.00)**	**(22,546.00)**	**(15,783.00)**	**(32,278.00)**
Net Short Term Debt Issued/Repaid	3,564.00	(1,838.00)	4,309.00	(714.00)	(61.00)	(2,343.00)	10,628.00	(13,974.00)	(96.00)	(218.00)	7,683.00
Long-Term Debt Issued	6,618.00	4,491.00	-	10,976.00	5,274.00	4,974.00	4,942.00	5,222.00	997.00	-	30,831.00
Long-Term Debt Repaid	(4,146.00)	(2,110.00)	(2,990.00)	(7,689.00)	(6,154.00)	(3,566.00)	(6,806.00)	(4,003.00)	(2,004.00)	(3,298.00)	(2,569.00)
Total Debt Issued/Repaid	**6,036.00**	**543.00**	**1,319.00**	**2,573.00**	**(941.00)**	**(935.00)**	**8,764.00**	**(12,755.00)**	**(1,103.00)**	**(3,516.00)**	**35,945.00**
Pref. Dividends Paid	(6,580.00)	(6,609.00)	(6,940.00)	(7,317.00)	(7,659.00)	(7,978.00)	(8,043.00)	(8,440.00)	(8,729.00)	(8,983.00)	(9,247.00)
Total Dividends Paid	**(6,580.00)**	**(6,609.00)**	**(6,940.00)**	**(7,317.00)**	**(7,659.00)**	**(7,978.00)**	**(8,043.00)**	**(8,440.00)**	**(8,729.00)**	**(8,983.00)**	**(9,247.00)**
Increase in CapItal Stocks	1,750.00	1,002.00	1,263.00	1,019.00	862.00	1,259.00	-	424.00	-	-	-
Decrease in Capital Stocks	(16,290.00)	(5,000.00)	(6,160.00)	(5,000.00)	(5,000.00)	(12,198.00)	(8,865.00)	-	-	(2,000.00)	-
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	46.00	(206.00)	(891.00)	(411.00)	(559.00)	(705.00)	(374.00)	11,114.00	(43.00)	(500.00)	(672.00)
Cash from Financing	**(15,038.00)**	**(10,270.00)**	**(11,409.00)**	**(9,136.00)**	**(13,297.00)**	**(20,557.00)**	**(8,518.00)**	**(9,657.00)**	**(9,875.00)**	**(14,999.00)**	**26,026.00**
Net Change in Cash	**(7,898.00)**	**1,160.00**	**299.00**	**(1,046.00)**	**(1,235.00)**	**(205.00)**	**125.00**	**475.00**	**159.00**	**(1,515.00)**	**2,448.00**
Supplemental Items											
Cash Interest Paid	1,729.00	1,550.00	1,302.00	1,451.00	1,518.00	1,311.00	1,587.00	1,641.00	1,467.00	1,442.00	2,215.00
Cash Taxes Paid	2,874.00	2,100.00	2,383.00	2,521.00	2,489.00	3,655.00	3,664.00	3,153.00	7,427.00	7,867.00	3,147.00
Free Cash Flow	16,478.00	15,885.00	13,291.00	14,078.00	14,846.00	13,785.00	10,542.00	12,151.00	29,869.00	26,031.00	4,793.00
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Bloomberg

Company In Depth Fundamentals - Multiples

Ticker:	PFE US EQUITY	Sort	Ascend
Period Type	Annuals	Consolidated	Yes
Accounting	Mixed		

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples												
		31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023
TEV / LTM Total Revenue	Close	3.9x	4.0x	4.4x	4.2x	4.6x	5.1x	6.4x	5.6x	4.2x	3.0x	3.8x
	Average	3.8x	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x	3.6x	2.2x
	High	4.2x	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	8.9x	4.0x	3.8x
	Low	3.5x	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x	3.0x	1.6x
TEV / LTM EBITDA	Close	9.3x	10.5x	12.7x	12.5x	12.0x	13.4x	12.5x	17.6x	13.6x	7.5x	30.6x
	Average	9.0x	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x	11.5x	5.6x
	High	10.0x	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x	13.1x	30.6x
	Low	8.3x	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x	7.5x	4.0x
TEV / LTM EBIT	Close	13.2x	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.5x	17.6x	8.7x	656.4x
	Average	13.5x	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	32.2x	14.9x	9.0x
	High	15.0x	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.5x	45.5x	16.9x	656.5x
	Low	12.5x	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x	8.7x	4.7x
Price / LTM EPS	Close	17.4x	17.5x	19.4x	15.5x	17.6x	19.3x	31.2x	20.7x	14.9x	8.3x	23.5x
	Average	16.9x	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	23.6x	12.6x	6.0x
	High	18.8x	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	34.4x	14.3x	23.5x
	Low	15.1x	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	20.7x	14.9x	8.3x	4.2x
Price / Book Value	Close	2.6x	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x	4.3x	3.0x	1.8x
	Average	2.5x	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x	3.6x	2.2x
	High	2.7x	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x	4.1x	3.0x
	Low	2.2x	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x	3.0x	1.5x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	116.6x	314.5x	--
	Average	--	--	--	--	--	--	--	--	116.6x	99.2x	226.6x
	High	--	--	--	--	--	--	--	--	116.6x	314.5x	314.6x
	Low	--	--	--	--	--	--	--	--	116.6x	82.4x	160.4x
Price / Cash Flow	Close	11.8x	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x	10.2x	9.8x	18.7x
	Average	12.2x	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x	8.6x	7.1x
	High	13.6x	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x	9.8x	18.7x
	Low	10.9x	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x	7.2x	5.0x
TEV / LTM FCF	Close	12.7x	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x	11.1x	11.0x	33.9x
	Average	13.3x	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x	9.3x	8.1x
	High	14.7x	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	28.0x	11.0x	33.9x
	Low	11.8x	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x	7.8x	5.6x
Dividend Yield	Close	3.1	3.3	3.5	3.7	3.6	3.2	3.7	4.2	2.7	3.1	5.7
	Average	3.2	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7	3.2	4.4
	High	3.6	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6	3.8	6.1
	Low	2.9	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5	2.8	3.1

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend		
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FQ	-9FQ	-8FQ	-7FQ	-6FQ	-5FQ	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
Ratios											
For the Fiscal Period Ending	**03/10/2021**	**31/12/2021**	**03/04/2022**	**03/07/2022**	**02/10/2022**	**31/12/2022**	**02/04/2023**	**02/07/2023**	**01/10/2023**	**31/12/2023**	**31/03/2024**
Profitability											
Return on Assets	10.9%	13.1%	14.6%	16.1%	15.9%	16.6%	15.3%	10.3%	5.1%	1.0%	-0.1%
Return on Capital	17.0%	20.8%	23.0%	25.7%	25.2%	25.6%	23.6%	15.7%	8.2%	2.6%	1.2%
Return on Equity	27.6%	31.3%	33.1%	37.3%	35.4%	36.3%	31.7%	23.1%	11.1%	2.3%	-0.3%
Margin Analysis											
Gross Margin	58.7%	59.2%	61.1%	68.8%	73.2%	60.3%	73.6%	74.6%	30.0%	46.9%	77.3%
SG&A Margin	11.3%	16.5%	9.7%	10.5%	14.3%	18.2%	18.1%	26.8%	24.2%	31.4%	23.2%
EBITDA Margin	31.8%	30.2%	31.7%	35.3%	38.4%	39.9%	40.2%	35.3%	22.6%	11.4%	8.2%
EBIT Margin	24.7%	23.9%	26.1%	30.4%	33.6%	34.8%	34.4%	27.9%	13.7%	0.7%	-3.7%
Earnings from Cont. Ops Margin	25.6%	12.5%	36.6%	44.0%	39.5%	18.1%	35.4%	15.1%	-25.9%	-32.3%	27.6%
Net Income Margin	33.9%	14.2%	30.6%	35.7%	38.0%	20.6%	30.0%	18.3%	-18.0%	-23.6%	20.9%
Normalized Net Income Margin	25.8%	25.0%	34.9%	38.4%	42.1%	23.7%	33.3%	22.7%	-12.7%	-1.3%	24.0%
Free Cash Flow Margin	42.5%	20.6%	23.0%	26.7%	40.2%	14.9%	0.4%	-16.7%	20.0%	29.4%	2.6%
Asset Turnover											
Total Asset Turnover	0.4x	0.5x	0.5x	0.6x	0.5x	0.5x	0.5x	0.4x	0.3x	0.3x	0.3x
Fixed Asset Turnover	4.8x	4.9x	6.3x	6.9x	6.7x	5.4x	5.8x	4.8x	4.1x	2.9x	3.1x
Accounts Receivable Turnover	6.3x	8.4x	8.0x	7.9x	7.1x	8.9x	7.3x	6.2x	5.1x	5.3x	4.7x
Inventory Turnover	2.7x	3.6x	4.0x	3.9x	3.8x	3.8x	3.0x	2.3x	2.7x	2.6x	2.3x
Short Term Liquidity											
Current Ratio	1.4x	1.4x	1.4x	1.4x	1.6x	1.2x	1.4x	2.1x	2.4x	0.9x	1.0x
Quick Ratio	1.0x	1.0x	0.9x	1.0x	1.2x	0.8x	0.9x	1.6x	1.8x	0.5x	0.6x
Cash from Ops. To Curr Liab.	0.7x	0.7x	0.6x	0.7x	0.8x	0.5x	0.5x	1.3x	1.4x	0.3x	0.3x
Avg. Days Sales Out.	58.8x	43.6x	45.5x	46.3x	51.0x	40.8x	49.9x	59.1x	71.9x	68.8x	77.0x
Avg. Days Inventory Out.	138.9x	101.3x	91.7x	92.2x	96.0x	95.9x	121.5x	158.6x	132.7x	140.2x	158.6x
Avg. Days Payable Out.	70.4x	56.7x	45.7x	48.2x	56.5x	66.0x	73.5x	94.4x	76.2x	94.3x	86.0x
Avg. Cash Conversion Cycle	127.3x	88.2x	91.5x	90.3x	90.4x	70.7x	97.9x	123.3x	128.5x	114.7x	149.6x
Long Term Solvency											
Total Debt/Equity	52.5%	53.4%	43.9%	46.1%	39.5%	40.7%	35.5%	65.8%	65.4%	84.0%	75.1%
Total Debt/Capital	34.4%	34.8%	30.5%	31.5%	28.3%	28.9%	26.2%	39.7%	39.5%	45.7%	42.9%
LT Debt/Equity	47.9%	50.1%	43.3%	39.3%	35.2%	37.1%	31.4%	62.0%	63.0%	72.1%	66.4%
LT Debt/Capital	31.3%	32.6%	30.0%	26.8%	25.2%	26.3%	23.1%	37.3%	38.0%	39.0%	37.8%
Total Liabilities/Total Assets	34.3%	33.8%	33.7%	30.9%	29.8%	30.0%	29.6%	39.2%	40.3%	39.5%	39.8%
EBIT / Interest Exp.	18.91x	9.50x	29.20x	41.70x	28.76x	14.01x	20.58x	3.78x	-4.93x	-6.69x	5.19x
EBITDA / Interest Exp.	23.04x	13.55x	32.88x	45.71x	32.56x	18.86x	25.26x	6.88x	-2.69x	-4.27x	7.39x
(EBITDA-CAPEX) / Interest Exp.	21.14x	10.40x	30.89x	43.15x	29.86x	15.66x	21.68x	5.08x	-3.85x	-5.78x	6.50x
Total Debt/EBITDA	1.81x	1.69x	1.24x	1.13x	0.96x	0.98x	0.96x	2.37x	4.09x	11.17x	15.38x
Net Debt/EBITDA	0.46x	0.42x	0.42x	0.20x	0.01x	0.41x	0.43x	0.75x	1.25x	9.28x	12.74x
Altman Z Score	4.18	4.81	5.06	4.99	4.95	5.63	5.37	3.99	3.62	3.05	3.21
Growth Over Prior Year											
Total Revenue	133.9%	104.9%	76.8%	46.8%	(5.8%)	1.9%	(28.0%)	(54.1%)	(41.5%)	(41.3%)	(19.5%)
Gross Profit	70.5%	60.9%	51.3%	60.4%	17.5%	3.8%	(13.2%)	(50.3%)	(76.1%)	(54.3%)	(15.4%)
EBITDA	96.3%	150.8%	79.6%	93.7%	35.2%	38.3%	(24.1%)	(73.9%)	(118.5%)	(149.8%)	(27.3%)
EBITA	105.9%	174.7%	84.5%	99.9%	37.2%	39.7%	(25.3%)	(76.2%)	(123.1%)	(160.6%)	(29.3%)
EBIT	151.1%	355.9%	100.5%	118.0%	45.5%	46.6%	(30.4%)	(84.3%)	(138.4%)	(205.1%)	(37.3%)
Earnings from Cont. Ops.	791.1%	464.4%	61.3%	69.5%	5.8%	39.8%	(29.5%)	(76.3%)	(127.6%)	(166.7%)	(43.7%)
Net Income	454.5%	300.6%	61.2%	78.1%	5.7%	47.2%	(29.5%)	(76.5%)	(127.7%)	(167.4%)	(43.8%)
Normalized Net Income	172.8%	224.2%	90.4%	91.6%	53.5%	(3.3%)	(31.1%)	(73.0%)	(117.6%)	(103.3%)	(42.0%)
Diluted EPS before Extra	793.8%	463.6%	59.3%	69.6%	5.6%	40.3%	(29.2%)	(76.3%)	(127.8%)	(167.8%)	(43.3%)
Accounts Receivable	18.8%	48.8%	34.1%	43.1%	35.1%	(4.6%)	(7.0%)	(33.5%)	(31.0%)	2.1%	(10.7%)
Inventory	(7.0%)	13.6%	17.5%	16.8%	10.1%	(0.9%)	(4.4%)	(1.4%)	7.3%	13.5%	14.3%
Net PP&E	0.2%	15.9%	7.8%	7.2%	7.0%	8.8%	12.9%	14.7%	15.7%	13.4%	10.3%
Total Assets	0.1%	12.7%	15.8%	14.9%	9.0%	8.7%	6.4%	12.7%	10.1%	14.9%	13.0%
Tangible Book Value	(90.6%)	(119.0%)	(126.3%)	(314.4%)	(14,559.9%)	(67.8%)	209.5%	(27.5%)	(65.7%)	(4,847.0%)	(679.7%)
Common Equity	16.0%	22.1%	20.1%	24.5%	22.4%	23.9%	22.5%	13.5%	4.6%	(6.9%)	(8.6%)
Cash from Ops.	418.1%	5.1%	44.1%	(27.7%)	(8.3%)	(31.8%)	(81.5%)	(114.8%)	(65.2%)	13.4%	(10.1%)
Capital Expenditures	10.2%	26.5%	16.1%	39.9%	36.1%	0.8%	27.1%	31.7%	(3.7%)	4.3%	(38.3%)
Levered Free Cash Flow	567.8%	3.7%	48.0%	(31.1%)	(10.9%)	(26.4%)	(98.8%)	(128.6%)	(70.9%)	15.9%	428.8%
Unlevered Free Cash Flow	(1,476.2%)	0.1%	101.4%	(39.7%)	(14.7%)	(49.6%)	(161.1%)	(185.7%)	(95.2%)	36.7%	(10.9%)
Dividend per Share	2.6%	2.6%	2.6%	0.0%	2.6%	2.6%	2.5%	2.5%	2.5%	2.5%	2.4%
CAGR Over Two Years											
Total Revenue	37.7%	51.0%	59.5%	67.7%	48.4%	44.5%	12.8%	(17.9%)	(25.8%)	(22.7%)	(23.9%)
Gross Profit	18.3%	29.9%	38.8%	54.1%	41.6%	29.2%	14.6%	(10.7%)	(47.0%)	(31.1%)	(14.4%)
EBITDA	(23.2%)	54.1%	58.8%	102.4%	62.9%	86.2%	16.7%	(28.9%)	--	--	(25.8%)
EBITA	(22.8%)	60.9%	62.4%	110.6%	68.1%	95.9%	17.4%	(31.0%)	--	--	(27.3%)
EBIT	(25.4%)	137.6%	76.1%	142.8%	91.1%	158.5%	18.1%	(41.5%)	--	--	(34.0%)
Earnings from Cont. Ops.	3.1%	--	78.1%	94.8%	207.0%	180.9%	6.6%	(36.6%)	--	--	(37.0%)
Net Income	3.0%	--	53.1%	68.5%	142.1%	147.8%	6.6%	(35.3%)	--	--	(37.1%)
Normalized Net Income	36.8%	104.4%	78.8%	95.0%	104.7%	77.2%	14.5%	(27.9%)	--	--	(36.8%)
Diluted EPS before Extra	2.5%	--	76.5%	93.8%	207.3%	181.2%	6.2%	(36.6%)	--	--	(36.6%)
Accounts Receivable	12.3%	30.2%	15.7%	28.9%	26.7%	17.5%	11.7%	(1.7%)	(3.5%)	(1.3%)	(8.8%)
Inventory	2.5%	13.2%	8.8%	10.5%	1.2%	5.2%	6.0%	7.2%	8.2%	6.1%	4.5%
Net PP&E	(1.9%)	11.5%	3.7%	3.9%	3.5%	12.3%	10.3%	10.9%	11.2%	11.1%	11.6%
Total Assets	2.5%	4.1%	5.1%	4.8%	4.5%	13.1%	11.0%	13.8%	9.5%	11.7%	9.7%
Tangible Book Value	(94.4%)	--	--	--	--	--	--	--	--	--	--
Common Equity	7.8%	10.6%	12.6%	16.4%	19.1%	23.0%	21.3%	18.9%	13.2%	7.4%	5.8%
Cash from Ops.	55.0%	25.3%	44.5%	51.6%	118.0%	(0.4%)	(48.3%)	--	(43.5%)	(5.9%)	(59.2%)
Capital Expenditures	4.6%	32.2%	19.7%	28.2%	22.4%	12.9%	43.4%	30.5%	14.5%	2.5%	4.6%
Levered Free Cash Flow	60.9%	24.0%	48.2%	54.8%	143.9%	(13.5%)	(86.5%)	--	(49.1%)	(7.7%)	(74.4%)
Unlevered Free Cash Flow	103.3%	50.3%	151.0%	129.0%	--	(29.0%)	--	--	(79.7%)	(17.0%)	--
Dividend per Share	4.1%	4.1%	2.6%	2.6%	2.6%	2.6%	2.5%	1.2%	2.5%	2.5%	2.5%
CAGR Over Three Years											
Total Revenue	21.8%	19.5%	25.1%	27.9%	21.3%	32.5%	22.4%	8.9%	8.8%	7.0%	0.8%
Gross Profit	10.0%	9.0%	13.6%	21.3%	18.0%	20.5%	18.6%	5.7%	(21.7%)	(8.6%)	3.5%
EBITDA	11.7%	3.6%	20.5%	31.6%	(7.3%)	48.7%	24.1%	2.2%	(179.9%)	(220.0%)	(0.3%)
EBITA	12.4%	3.5%	22.3%	33.8%	(7.3%)	53.5%	25.4%	1.8%	(186.7%)	(232.5%)	(0.8%)
EBIT	17.8%	9.0%	28.2%	42.0%	(6.8%)	102.3%	29.2%	(2.5%)	(211.9%)	(281.5%)	(4.4%)
Earnings from Cont. Ops.	25.7%	(310.6%)	26.5%	25.0%	4.0%	(268.6%)	20.8%	(3.5%)	(227.6%)	(273.0%)	(13.8%)
Net Income	25.6%	(305.0%)	26.5%	25.2%	3.9%	(245.6%)	18.2%	(12.6%)	(217.5%)	(258.4%)	(13.9%)
Normalized Net Income	18.1%	(269.9%)	29.0%	41.9%	42.2%	59.2%	30.1%	1.0%	(190.4%)	(146.7%)	(8.7%)
Diluted EPS before Extra	27.5%	(306.9%)	26.3%	24.8%	3.5%	(266.1%)	20.1%	(3.8%)	(237.9%)	(275.0%)	(13.8%)
Accounts Receivable	5.9%	12.7%	11.3%	15.7%	19.4%	17.4%	7.6%	3.9%	3.5%	12.1%	3.7%
Inventory	1.8%	6.5%	7.5%	8.3%	5.0%	8.3%	4.2%	6.4%	3.2%	8.2%	8.6%
Net PP&E	0.9%	9.8%	0.8%	1.0%	1.0%	10.6%	6.7%	7.4%	7.4%	12.7%	10.3%
Total Assets	2.2%	4.4%	5.8%	7.2%	4.7%	5.6%	5.6%	7.4%	6.3%	13.7%	11.7%
Tangible Book Value	(84.6%)	(148.6%)	(143.6%)	(167.4%)	(176.9%)	(136.2%)	(164.1%)	(159.9%)	(158.4%)	42.7%	62.6%
Common Equity	2.0%	6.8%	11.0%	13.6%	12.5%	14.9%	15.8%	15.5%	14.1%	12.1%	10.4%
Cash from Ops.	27.2%	7.7%	56.8%	46.3%	30.1%	2.0%	(27.1%)	(169.8%)	18.3%	(2.3%)	(37.8%)
Capital Expenditures	4.2%	13.2%	11.8%	16.2%	14.2%	20.8%	36.4%	26.0%	13.0%	10.0%	8.5%
Levered Free Cash Flow	29.4%	6.7%	68.3%	51.5%	32.1%	4.2%	(69.9%)	(188.1%)	20.1%	(4.6%)	(54.1%)
Unlevered Free Cash Flow	43.5%	9.3%	(265.4%)	241.4%	57.2%	4.4%	(256.8%)	(265.0%)	(182.9%)	(11.7%)	(203.1%)
Dividend per Share	4.7%	4.7%	3.6%	3.6%	3.6%	3.6%	2.6%	2.6%	2.6%	2.6%	2.5%
CAGR Over Five Years											
Total Revenue	13.0%	11.8%	15.0%	16.6%	11.4%	12.1%	7.5%	(1.1%)	(0.1%)	0.4%	2.6%
Gross Profit	7.2%	6.3%	8.7%	13.3%	9.9%	7.0%	5.6%	(2.1%)	(17.9%)	(9.3%)	1.5%
EBITDA	11.1%	6.1%	13.7%	20.3%	14.1%	8.8%	7.8%	(8.8%)	(181.0%)	(194.2%)	(0.7%)
EBITA	12.3%	7.6%	14.5%	21.4%	15.1%	9.6%	8.3%	(9.7%)	(185.2%)	(198.7%)	(0.7%)
EBIT	15.3%	13.1%	18.6%	26.7%	19.5%	13.7%	10.6%	(13.5%)	(198.2%)	(214.8%)	(1.5%)
Earnings from Cont. Ops.	43.2%	36.2%	20.3%	26.3%	24.8%	(16.5%)	9.2%	(9.6%)	(189.7%)	54.2%	(4.3%)
Net Income	43.2%	34.4%	20.3%	26.4%	24.8%	(16.5%)	9.3%	(9.7%)	(189.6%)	53.6%	(4.3%)
Normalized Net Income	17.3%	18.3%	22.8%	25.1%	23.8%	13.9%	11.3%	(4.2%)	(185.1%)	(33.4%)	(3.0%)
Diluted EPS before Extra	45.4%	38.9%	21.9%	27.7%	26.3%	(15.5%)	10.5%	(8.8%)	(190.5%)	53.2%	(4.2%)
Accounts Receivable	3.9%	6.9%	8.3%	9.8%	10.0%	5.9%	5.4%	0.7%	2.0%	6.9%	2.7%
Inventory	2.9%	6.0%	6.1%	6.6%	3.7%	3.5%	3.2%	5.0%	4.5%	6.3%	6.3%
Net PP&E	1.7%	5.9%	2.7%	2.6%	2.7%	6.8%	4.1%	4.7%	4.9%	10.3%	5.0%
Total Assets	0.1%	1.1%	1.7%	3.0%	2.6%	2.8%	3.5%	5.9%	5.1%	7.3%	7.3%
Tangible Book Value	(70.1%)	(157.8%)	(155.5%)	(171.2%)	(181.3%)	(149.3%)	(174.5%)	(171.9%)	(170.9%)	11.9%	6.3%
Common Equity	3.6%	5.3%	7.1%	8.4%	8.8%	6.1%	7.6%	7.3%	6.3%	7.0%	9.4%
Cash from Ops.	18.0%	0.6%	32.8%	20.3%	15.2%	(8.2%)	(9.4%)	(179.3%)	(8.1%)	2.0%	(8.5%)
Capital Expenditures	7.4%	7.6%	12.4%	10.9%	13.3%	7.4%	24.2%	16.6%	8.2%	8.8%	8.9%
Levered Free Cash Flow	18.9%	(0.6%)	36.9%	21.6%	15.4%	(10.7%)	(46.0%)	(190.9%)	(10.9%)	0.7%	(20.8%)
Unlevered Free Cash Flow	26.4%	(3.4%)	(238.4%)	42.5%	21.9%	(21.0%)	38.7%	(225.3%)	(34.3%)	(2.1%)	19.7%
Dividend per Share	5.4%	5.4%	4.6%	4.6%	4.6%	4.6%	3.8%	3.8%	3.8%	3.8%	3.1%

Bloomberg

Company In Depth Fundamentals - Capital Structure Summary

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting / Change / USD
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
WACC					
For the Fiscal Period Ending	**02/04/2023**	**02/07/2023**	**01/10/2023**	**31/12/2023**	**31/03/2024**
	%	**%**	**%**	**%**	**%**
Equity					
Cost of Equity	7.6%	8.4%	8.6%	8.9%	7.9%
Weight of Equity	86.5%	76.0%	74.7%	68.4%	69.3%
+ Debt					
Cost of Debt	4.0%	4.6%	5.7%	5.1%	5.0%
Weight of Debt	13.5%	24.0%	25.3%	31.6%	30.7%
+ Preferred Equity					
Cost of Pref Equity	--	--	--	--	--
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	**7.1%**	**7.5%**	**7.9%**	**7.7%**	**7.0%**

Capital Structure										
For the Fiscal Period Ending	**02/04/2023**		**02/07/2023**		**01/10/2023**		**31/12/2023**		**31/03/2024**	
Currency	***USD***		***USD***		***USD***		***USD***		***USD***	
	Millions	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***
Hist Market Cap										
ST Borrowings	4,188.0	*1.6%*	3,985.0	*1.5%*	2,548.0	*1.0%*	10,877.0	*4.6%*	8,232.0	*3.6%*
LT Borrowings	31,704.0	*11.9%*	61,356.0	*22.5%*	61,048.0	*24.3%*	64,164.0	*27.0%*	61,307.0	*27.0%*
Pref Equity	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*	0.0	*0.0%*
Total Capital	**266,208.0**	***100.0%***	**272,399.6**	***100.0%***	**250,873.8**	***100.0%***	**237,589.3**	***100.0%***	**226,798.3**	***100.0%***

Debt Summary Data										
For the Fiscal Period Ending	**02/04/2023**		**02/07/2023**		**01/10/2023**		**31/12/2023**		**31/03/2024**	
Currency	***USD***		***USD***		***USD***		***USD***		***USD***	
	Millions	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***	***Millions***	***% of Total***
Total Commercial Paper	--	--	--	--	0.0	*0.0%*	0.0	*0.0%*	--	--
Total Revolving Credit	7,000.0	*19.5%*	7,000.0	*10.7%*	7,000.0	*11.0%*	15,031.0	*20.0%*	15,000.0	*21.6%*
Total Capital Leases	--	--	--	--	--	--	--	--	--	--
General/Other Borrowings				*89.3%*	56,596.0	*89.0%*		*80.0%*	54,539.0	*78.4%*
Total Principal Due	**35,892.0**	***100.0%***	**65,341.0**	***100.0%***	**63,596.0**	***100.0%***	**75,041.0**	***100.0%***	**69,539.0**	***100.0%***
Total Debt Outstanding	**35,892.0**		**65,341.0**		**63,596.0**		**75,041.0**		**69,539.0**	
Additional Totals										
Total Cash & ST Investments	19,972.0	*55.6%*	44,785.0	*68.5%*	44,181.0	*69.5%*	12,690.0	*16.9%*	11,928.0	*17.2%*
Net Debt	15,920.0	*44.4%*	20,556.0	*31.5%*	19,415.0	*30.5%*	62,351.0	*83.1%*	57,611.0	*82.8%*
Total Short-Term Borrowings	4,188.0	*11.7%*	3,985.0	*6.1%*	2,548.0	*4.0%*	10,877.0	*14.5%*	8,232.0	*11.8%*
Curr. Port. of LT Debt/Cap. Leases	4,188.0	*11.7%*	3,985.0	*6.1%*	2,548.0	*4.0%*	10,877.0	*14.5%*	8,232.0	*11.8%*
Long-Term Debt (Incl. Cap. Leases)	31,704.0	*88.3%*	61,356.0	*93.9%*	61,048.0	*96.0%*	64,164.0	*85.5%*	61,307.0	*88.2%*
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--
Credit Ratios										
Net Debt/EBITDA	0.4x		0.7x		1.2x		9.3x		12.7x	
Total Debt/EBITDA	1.0x		2.4x		4.1x		11.2x		15.4x	
Operating Income/Total Debt	0.2x		0.0x		-0.1x		-0.1x		0.1x	
LTM FCF/Total Debt	0.6x		0.2x		0.1x		0.1x		0.1x	
LTM CFO/Total Debt	0.7x		0.2x		0.1x		0.1x		0.1x	
EBIT/Interest Expense	20.6x		3.8x		-4.9x		-6.7x		5.2x	
EBIT/Total Interest Expense	20.6x		3.8x		-4.9x		-6.7x		5.2x	
Degree of Financial Leverage	1.1x		1.4x		--		--		1.2x	
(EBITDA-CAPEX)/Interest Expense	21.7x		5.1x		-3.9x		-5.8x		6.5x	
EBITDA/Total Interest Expense	25.3x		6.9x		-2.7x		-4.3x		7.4x	
Debt Schedule										
Debt Schedule In Yr 1	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 2	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 3	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 4	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule Beyond Yr 5	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Total Debt	**35,892.0**	***100.0%***	**65,341.0**	***100.0%***	**63,596.0**	***100.0%***	**71,888.0**	***100.0%***	**69,539.0**	***100.0%***
Capital Lease Schedule										
Capital Leases - Year 1	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Future Value of Capital Leases	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
Present Value of ST Capital Leases	--		--		--		--		--	
Present Value of LT Capital Leases	--		--		--		--		--	
Operating Leases (Rental Expense) Schedule										
Rental Expense - Year 1	--	--	--	--	--	--	639.0	*16.7%*	--	--
Rental Expense - Year 2	--	--	--	--	--	--	474.0	*12.4%*	--	--
Rental Expense - Year 3	--	--	--	--	--	--	387.0	*10.1%*	--	--
Rental Expense - Year 4	--	--	--	--	--	--	319.0	*8.3%*	--	--
Rental Expense - Year 5	--	--	--	--	--	--	262.0	*6.9%*	--	--
Rental Expense - Years 2 - 3	--	--	--	--	--	--	861.0	*22.5%*	--	--
Rental Expense - Years 4 - 5	--	--	--	--	--	--	581.0	*15.2%*	--	--
Rental Expense - Years 2 - 5	--	--	--	--	--	--	1,442.0	*37.7%*	--	--
Rental Expense Beyond Year 5	--	--	--	--	--	--	1,743.0	*45.6%*	--	--
Total Sublease Income	--	--	--	--	--	--	--	--	--	--
Future Min Oper Lease Obligations	**--**	**--**	**--**	**--**	**--**	**--**	**3,824.0**	***100.0%***	**--**	**--**
Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	--	--	--	--	--	--	--	--
Contractual Obligations- Years 2-3	--	--	--	--	--	--	--	--	--	--
Contractual Obligations- Years 4-5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Contractual Obligations	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**	**--**
Purchase Obligations	**--**		**--**		**--**		**5,200.0**		**--**	
Interest Rate Data										
W/Avg. Interest Rate - Long-term Debt	--		--		--		--		--	

Bloomberg Company In Depth Fundamentals - Segments

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE							31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023
Revenue by Product											
For the Fiscal Period Ending	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Revenue	**51,584.00**	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,908.00**	**81,288.00**	**100,330.00**	**58,496.00**
Biopharma	47,878.00	25,600.00	26,758.00	29,197.00	31,422.00	37,558.00	38,344.00	41,651.00	79,557.00	98,989.00	57,186.00
Business Innovation	3,706.00	24,005.00	22,093.00	23,627.00	21,124.00	12,484.00	2,828.00	-	1,731.00	1,342.00	1,309.00
Pfizer Ignite	-	-	-	-	-	3,605.00	-	-	-	-	-
Pfizer Centreone	-	-	-	-	-	-	-	-	-	-	-
Reconciling Items	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography											
For the Fiscal Period Ending	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Revenue	**51,584.00**	**49,605.00**	**48,851.00**	**52,824.00**	**52,546.00**	**53,647.00**	**40,905.00**	**41,908.00**	**81,288.00**	**100,330.00**	**58,496.00**
United States	20,274.00	19,073.00	21,704.00	26,369.00	26,026.00	25,329.00	20,593.00	21,455.00	29,746.00	42,473.00	27,088.00
Emerging Markets	11,739.00	11,719.00	11,136.00	10,420.00	11,400.00	12,651.00	8,828.00	8,370.00	20,702.00	21,982.00	11,996.00
	11,225.00	11,499.00	9,713.00	9,304.00	8,510.00	9,116.00	7,729.00	7,788.00	18,334.00	20,097.00	11,650.00
	8,346.00	7,314.00	6,298.00	6,731.00	6,610.00	6,551.00	4,022.00	4,038.00	12,505.00	15,778.00	7,761.00
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Bloomberg

Company In Depth Fundamentals - Pension

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	543.00	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00	116.00	85.00
Interest Cost	1,111.00	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00	691.00	876.00
Expected Return on Plan Assets	(1,406.00)	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,321.00)	(1,379.00)	(1,158.00)	(1,082.00)
Pension Expense (Income)	928.00	402.00	1,203.00	696.00	695.00	(2.00)	331.00	70.00	(2,011.00)	(129.00)	(423.00)
Other Postretirement Cost											
Service Cost	61.00	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00	29.00	12.00
Interest Cost	166.00	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00	27.00	21.00
Expected Return on Plan Assets	(55.00)	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(36.00)	(39.00)	(47.00)	(44.00)
Other Postretirement Benefits Expense (I	163.00	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(118.00)	(372.00)	(578.00)	(90.00)
Pension Funded Status											
Fair Value of Plan Assets	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00
Actual Return (Loss) on Plan Assets	2,294.00	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	2,842.00	--	--	--
Employer Contribution	557.00	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	1,629.00	451.00	156.00	154.00
Benefits Paid	(1,017.00)	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)	(816.00)	(791.00)
Projected Benefit Obligation	25,633.00	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00	18,917.00	18,048.00
Over(Under) Funded Pension	(4,514.00)	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)	(1,181.00)	(561.00)
Accumulated Benefit Obligation	18,346.00	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	82.39	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99	93.76	96.89
Other Postretirement Funded Status											
Fair Value of Plan Assets	741.00	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00	647.00	636.00
Actual Return (Loss) on Plan Assets	98.00	45.00	(3.00)	44.00	39.00	(22.00)	50.00	69.00	--	--	--
Employer Contribution	244.00	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00	65.00	(15.00)
Benefits Paid	(314.00)	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	(201.00)	--	--	--
Projected Benefit Obligation	3,438.00	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00	410.00	450.00
Over(Under) Funded Post Ret Benefits	(2,697.00)	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)	237.00	186.00
Other Post-Retirement Funding Ratio	21.55	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68	157.80	141.33
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.37	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80	6.30	7.50
Discount Rate used on Plan Liabilities	4.66	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.90	5.40	5.40
Rate of Compensation Increase	2.92	2.76	2.80	2.74	2.80	2.80	-	-	--	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80	6.30	7.50
Discount Rate used on Plan Liabilities	5.10	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90	5.50	5.40
Health Care Cost Trend Projected(next y	7.30	7.00	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00
Asset Category - Equities %	51.65	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00	30.00	30.00
Asset Category - Debt %	30.05	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00	60.00	50.00
Asset Category - Real Estate %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Company Stock %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Cash %	2.79	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00	5.00	5.00
Asset Category - Other %	11.36	18.41	21.20	19.70	18.30	18.20	17.00	16.60	12.50	5.00	15.00
Expected Pension Payments											
Year 1	1,368.00	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00	1,346.00	1,381.00
Year 2	1,313.00	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00	1,312.00	1,268.00
Year 3	1,320.00	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00	1,292.00	1,265.00
Year 4	1,396.00	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00	1,280.00	1,259.00
Year 5	1,511.00	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00	1,277.00	1,244.00
Beyond Year 5	7,383.00	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00	6,287.00	6,077.00
Expected Postretirement Benefits											
Year 1	286.00	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00	42.00	43.00
Year 2	285.00	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00	43.00	45.00
Year 3	293.00	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00	44.00	46.00
Year 4	303.00	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00	44.00	47.00
Year 5	311.00	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00	43.00	47.00
Beyond Year 5	1,661.00	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00	192.00	218.00

Bloomberg

Company In Depth Fundamentals - Supplemental

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting / Change / USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed

Pfizer Inc

Sector: Salud **Industry: Productos farmacéuticos** **Sub-Industry: Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Supplemental											
For the Fiscal Period Ending	**31/12/2013**	**31/12/2014**	**31/12/2015**	**31/12/2016**	**31/12/2017**	**31/12/2018**	**31/12/2019**	**31/12/2020**	**31/12/2021**	**31/12/2022**	**31/12/2023**
Currency	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***	***USD***
Options Activity											
Options Granted During Period	45.01	44.60	46.13	1.37	1.38	1.37	1.18	1.76	0.78	0.43	0.64
Options Outstanding End Of Period	299.65	249.11	232.55	186.68	150.76	103.79	88.60	75.40	44.87	35.28	28.45
Options Exercisable End of Period	163.06	122.62	109.56	105.86	108.75	100.08	85.37	71.73	41.58	32.46	26.67
Price											
Weighted Average Fair Value per Option	3.13	-	-	-	-	-	-	-	-	-	-
Avg Exercise Price (Options Outstanding)	24.33	24.05	26.41	26.86	27.27	27.69	28.39	28.31	30.20	31.47	32.66
Avg Exercise Price (Options Exercisable)	26.06	21.19	-	-	24.49	27.47	28.04	27.97	29.81	31.18	32.19
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	1.16	3.72	1.89	1.55	2.23	2.85	2.55	1.15	1.27	1.93	4.03
Stock Opt Valuation - Expected Life (Yrs)	6.50	6.50	6.75	6.75	6.75	6.75	5.13	5.12	6.75	6.50	6.50
Stock Opt Valuation - Expected Volatil (%)	19.68	19.76	18.34	21.64	18.39	20.02	18.34	20.99	26.54	29.21	23.23
Stock Opt Valuation - Dividend Yield (%)	3.45	3.18	3.19	3.85	3.69	3.73	3.27	4.36	4.51	3.42	3.80
Stock Expense											
Expense For Stock-Based Compensation	523.00	586.00	669.00	691.00	840.00	949.00	718.00	780.00	1,200.00	872.00	525.00
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-